Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Down 9.6% – What’s Next?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) was down 9.6% during mid-day trading on Tuesday . The stock traded as low as $24.40 and last traded at $24.5950. Approximately 3,622 shares changed hands during trading, a decline of 98% from the average daily volume of 205,399 shares. The stock had previously closed at $27.22.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on CHGCY shares. UBS Group raised shares of Chugai Pharmaceutical to a “strong-buy” rating in a research note on Tuesday, January 27th. Smbc Nikko Sec. raised shares of Chugai Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Strong Buy”.

Chugai Pharmaceutical Price Performance

The company’s fifty day simple moving average is $28.49 and its two-hundred day simple moving average is $27.06. The stock has a market cap of $90.38 billion, a price-to-earnings ratio of 30.51 and a beta of 0.69.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its quarterly earnings data on Friday, April 24th. The company reported $0.22 earnings per share for the quarter. The firm had revenue of $2.05 billion for the quarter. Chugai Pharmaceutical had a net margin of 34.98% and a return on equity of 22.40%.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.